NewAmsterdam Pharma Company NV (NASDAQ: NAMS) on Monday, plunged -5.93% from the previous trading day, before settling in for the closing price of $21.76. Within the past 52 weeks, NAMS’s price has moved between $15.19 and $27.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 34.27% over the last five years. The company achieved an average annual earnings per share of 29.98%. With a float of $57.95 million, this company’s outstanding shares have now reached $108.06 million.
The firm has a total of 68 workers. Let’s measure their productivity. In terms of profitability, gross margin is 99.96%, operating margin of -370.98%, and the pretax margin is -512.33%.
NewAmsterdam Pharma Company NV (NAMS) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of NewAmsterdam Pharma Company NV is 47.10%, while institutional ownership is 48.02%. The most recent insider transaction that took place on Mar 26 ’25, was worth 25,521. In this transaction Director of this company bought 1,135 shares at a rate of $22.49, taking the stock ownership to the 3,013,569 shares. Before that another transaction happened on Mar 26 ’25, when Company’s Affiliate proposed sale 12,258 for $23.41, making the entire transaction worth $286,960.
NewAmsterdam Pharma Company NV (NAMS) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.98% per share during the next fiscal year.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Trading Performance Indicators
NewAmsterdam Pharma Company NV (NAMS) is currently performing well based on its current performance indicators. A quick ratio of 8.08 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 49.34.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.60, a number that is poised to hit -0.50 in the next quarter and is forecasted to reach -1.80 in one year’s time.
Technical Analysis of NewAmsterdam Pharma Company NV (NAMS)
Analysing the last 5-days average volume posted by the [NewAmsterdam Pharma Company NV, NAMS], we can find that recorded value of 1.04 million was better than the volume posted last year of 0.89 million. As of the previous 9 days, the stock’s Stochastic %D was 13.48%. Additionally, its Average True Range was 1.31.
During the past 100 days, NewAmsterdam Pharma Company NV’s (NAMS) raw stochastic average was set at 32.74%, which indicates a significant increase from 18.71% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 35.20% in the past 14 days, which was lower than the 80.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $21.67, while its 200-day Moving Average is $20.13. Now, the first resistance to watch is $21.84. This is followed by the second major resistance level at $23.21. The third major resistance level sits at $24.36. If the price goes on to break the first support level at $19.32, it is likely to go to the next support level at $18.17. Should the price break the second support level, the third support level stands at $16.80.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Key Stats
Market capitalization of the company is 2.25 billion based on 109,818K outstanding shares. Right now, sales total 45,560 K and income totals -241,600 K. The company made 12,770 K in profit during its latest quarter, and -92,180 K in sales during its previous quarter.
